Back to Authors

Vargas‐González, Juan‐Camilo

https://orcid.org/0000-0002-1719-2200

Mayo Clinic

University Health Network

Citations 3

Sex Differences in Neuropsychiatric Symptoms Associated with Agitation in Frontotemporal Lobar Degeneration
Sakran, Celine N., Dimal, Nico Paulo, Cortez, Kasey, Heuer, Hilary W. , Forsberg, Leah K. , Barmada, Sami J. , Clark, David G., Darby, Ryan, Dickerson, Brad C., Domoto‐Reilly, Kimiko, Galasko, Douglas R., Geschwind, Daniel H., Ghoshal, Nupur , Graff‐Radford, Neill R., Grant, Ian , Irwin, David J., Honig, Lawrence S., Kantarci, Kejal, Litvan, Irene, Mackenzie, Ian R. , Masdeu, Joseph C. , MENDEZ, M, Onyike, Chiadi, Pascual, Belén , Pressman, Peter , Ramos, Eilana, Rogalskı, Emily , Boeve, Brad F, Boxer, Adam L., Rosen, Howard J., Tartaglia, Carmela M., Pascual, Belen , Barmada, Sami , Vargas‐González, Juan‐Camilo , Dimal, Nico , Appleby, Brian S. , Bozoki, Andrea C , Clark, David G., Cobigo, Yann , Dickerson, Brad C., Domoto‐Reilly, Kimiko , Galasko, Douglas R., Geschwind, Daniel H. , Graff‐Radford, Neill R. , Irwin, David J. , Hsiung, Ging‐Yuek Robin , Honig, Lawrence S. , Kantarci, Kejal , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , Mendez, Mario F. , Ramos, Eliana Marisa , Roberson, Erik D. , Boxer, Adam L. , Rosen, Howard J.

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S3 | Pages: No page available

10.1002/alz70857_103036 Get It

Abstract Background Agitation is a clinically significant symptom contributing to behavioral and psychological symptoms of dementia (BPSD) but is poorly understood across the different syndromes related to Frontotemporal Lobar Degeneration (FTLD). This study investigates sex differences in agitation across FTLD‐related syndromes and its relationship to various neuropsychiatric symptoms (NPS). Method We analyzed data from 1,654 participants (916 males, 738 females; average ages 65.8 and 65.9, respectively) from the National Alzheimer's Coordinating Center (NACC) and ARTFL‐LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) study with a FTLD‐related syndrome: behavioral variant FTD (bvFTD), Primary Progressive Aphasia (non‐fluent variant (nfvPPA), semantic variant (svPPA)), Corticobasal syndrome (CBS) and Progressive Supranuclear Palsy (PSP). Participants’ symptoms were assessed using the Neuropsychiatric Inventory (NPI). Prevalence ratios and odds ratios were computed to assess the likelihood of NPS comorbidities when agitation was present in males and females. Principal Component Analysis (PCA) was performed to identify NPS associated with agitation and how they varied by sex. Result Males were more likely to experience anxiety (bvFTD: p <0.001, CBS: p <0.01, PSP: p <0.0001), apathy (nfvPPA: p <0.01, PSP: p <0.01), depression (bvFTD: p <0.0001, PSP<0.01), disinhibition (nfvPPA: p <0.0001), PSP: p <0.001), and motor symptoms (bvFTD: p <0.01, CBS: p <0.01) when agitation was present. In contrast, females had a higher likelihood of experiencing disinhibition in svPPA ( p <0.001). These findings suggest that agitation is associated with a wider range of NPS in males than in females. Agitation and NPS are especially prominent in males with PSP. Conclusion This study reveals significant sex differences in NPS in FTLD‐related syndromes when agitation is present. Males and especially PSP, are more likely to experience a broader range of NPS in association with agitation. These findings underscore the need for further investigation into the underlying mechanisms driving these sex differences, particularly focusing on the neurobiological impact of agitation, the recognition of symptoms in the presence of greater behavioral disturbances, and potential variations from informant reports. Understanding these factors will provide valuable insights into the role of agitation in the presentation of NPS across FTLD‐related syndromes. Ultimately, addressing these gaps will enhance our ability to effectively treat and manage agitation in both male and female patients with FTLD‐related syndromes.
Female Informants are associated with higher CDR PLUS NACC‐FTLD scores in patients with Frontotemporal Dementia
Alotibi, Hessah A , Cortez, Kasey, Dimal, Nico Paulo, Heuer, Hilary W. , Forsberg, Leah K. , Barmada, Sami J. , Clark, David G., Darby, Ryan, Dickerson, Brad C., Domoto‐Reilly, Kimiko, Galasko, Douglas R., Geschwind, Daniel H., Ghoshal, Nupur , Graff‐Radford, Neill R., Grant, Ian , Irwin, David J., Hsiung, Ging‐Yuek Robin, Honig, Lawrence S., Kantarci, Kejal, Litvan, Irene, Mackenzie, Ian R. , Masdeu, Joseph C. , MENDEZ, M, Onyike, Chiadi, Pascual, Belén , Pressman, Peter , Ramos, Eilana, Rogalskı, Emily , Knopman, D S, Boeve, Brad F, Boxer, Adam L., Rosen, Howard J., Tartaglia, Carmela M., ALLFTD, Pascual, Belen , Barmada, Sami , Vargas‐González, Juan‐Camilo , Dimal, Nico , Appleby, Brian S. , Bozoki, Andrea C , Clark, David G., Cobigo, Yann , Dickerson, Brad C., Domoto‐Reilly, Kimiko , Galasko, Douglas R., Geschwind, Daniel H. , Graff‐Radford, Neill R. , Irwin, David J. , Hsiung, Ging‐Yuek Robin , Honig, Lawrence S. , Kantarci, Kejal , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , Mendez, Mario F. , Ramos, Eliana Marisa , Roberson, Erik D. , Knopman, David S. , Boxer, Adam L. , Rosen, Howard J.

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S3 | Pages: No page available

10.1002/alz70857_100828 Get It

Abstract Background Staging disease severity in dementia research requires input from an informant. The Clinical Dementia Rating Sum of Boxes (CDR) is the most used instrument for staging in Alzheimer's Disease (AD); but has been expanded to stage patients with frontotemporal lobar degeneration (FTLD) with the CDR PLUS NACC‐FTLD. An informant effect on the CDR has been reported in AD. The aim of this study is to evaluate whether informant characteristics influence the CDR PLUS NACC‐FTLD in a large cohort of participants with frontotemporal dementia (FTD). Method We included participants with a FTLD‐related syndrome from the ALLFTD study. We included participants with a CDR PLUS NACC‐FTLD higher than 0, information on the Montreal Cognitive Assessment (MoCA) scores, and the Neuropsychiatric Inventory Questionnaire (NPI‐Q). We performed a conditional growth model using multilevel linear regression analysis. We performed an exploratory stratified analysis by patient sex. Result We included 1411 participants, totalling 2063 visits. The patient's age at the initial visit was 64.7±9.4 years and 44.0% were females. Females were 69.2% of the informants, and the relationship was 79.1% spouse or partner, 10.6% children, 4.1% were siblings and 6.2% other. The CDR PLUS NACC‐FTLD scores were affected by informant characteristics. The CDR PLUS NACC‐FTLD scores were 0.41 (CI 95%:0.08 to 0.75) higher with female informants. The frequency of visits was associated with a CDR PLUS NACC‐FTLD score 0.86 higher (CI 95%:0.17 to 0.56) when visiting at least once a week, 1.46 higher (CI 95%:0.46 to 2.47) when visiting daily, and 0.83 higher (CI 95%:0.06 to 1.60) when living with the patient compared with visiting less than once a week. As expected, CDR‐FLTD scores increased with lower MoCA and higher NPI‐Q scores. In the stratified analysis by sex, we found that female informant was associated with higher CDR PLUS NACC‐FTLD scores only when patients were male. Conclusion We found that the CDR PLUS NACC‐FTLD is influenced by informant sex and frequency of visits in patients with FTLD‐related syndromes. These results are similar to those observed in AD patients and underscore the need to recognize that informant characteristics may impact dementia severity scales.
Psychotropic medication usage in sporadic versus genetic behavioral‐variant frontotemporal dementia
Vargas‐González, Juan‐Camilo , Dimal, Nico , Cortez, Kasey, Heuer, Hilary W. , Forsberg, Leah K. , Barmada, Sami J. , Darby, R. Ryan , Domoto‐Reilly, Kimiko , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R., Grant, Ian , Kantarci, Kejal , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Pascual, Belén , Pressman, Peter , Ramos, Eliana Marisa , Roberson, Erik D. , Rogalskı, Emily , Boxer, Adam L. , Rosen, Howie, Damme, Philip Van , Boeve, Brad F, Roberson, Erik , Kantarci, Kejal , Van Damme, Philip , Pascual, Belen , Domoto-Reilly, Kimiko , Barmada, Sami , Appleby, Brian S. , Bozoki, Andrea C , Clark, David , Cobigo, Yann , Dickerson, Bradford Clark , Galasko, Douglas , Graff‐Radford, Neill R. , Irwin, David J. , Hsiung, Ging‐Yuek Robin , Honig, Lawrence S. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , Boeve, Bradley F. , Tartaglia, Maria Carmela

Alzheimer's & Dementia | December 23, 2024 | Volume: 21 | Issue: 2 | Pages: No page available

10.1002/alz.14448 Get It

Abstract INTRODUCTION Psychotropic medication (PM) use in behavioral‐variant frontotemporal dementia (bvFTD) is higher than in other dementias. However, no information exists on whether PM use differs between sporadic and genetic bvFTD. METHODS We analyzed data from sporadic and genetic bvFTD participants with PM prescriptions in the Advancing Research and Treatment in Frontotemporal Lobar Degeneration/Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects study. We estimated ordinal odds ratio (OOR) of having more PM comparing sporadic and genetic bvFTD. Finally, we explored the neuropsychiatric symptom (NPS) combinations using classification and regression trees (CART). RESULTS We included 263 with sporadic and 193 with genetic bvFTD. The OOR for sporadic bvFTD to be on PM was 1.75 (95% confidence interval: 1.21 to 2.53) for the fully adjusted model. CART revealed the most common NPS combination was apathy + personality changes in 18% of participants. DISCUSSION Participants with sporadic bvFTD were twice as likely to be on PM compared to genetic bvFTD. The reason for increased PM usage in sporadic bvFTD participants should be further investigated. Highlights We report on patients with behavioral variant frontotemporal dementia (bvFTD). We evaluated the psychotropic medication (PM) prescription at baseline in the cohort. Patients with sporadic bvFTD had more prescriptions for PM than genetic patients. The frequency of symptoms combination was different in sporadic and genetic bvFTD.